Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2233–2256 of 16,135 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorder Clear all

Conditions: Metastatic Triple Negative Breast Cancer
Interventions: Combination of Veliparib + Lapatinib; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Breast Neoplasms, Neoplasms, Hormone-Dependent
Interventions: Atamestane, Toremifene, Letrozole, Aromatase inhibition, Estrogen receptor blocker, Hormone therapy, Endocrine therapy, Antiestrogen therapy; Drug · Procedure
Lead sponsor: Intarcia Therapeutics; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 842 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 49
States / cities: Mobile, Alabama • Tuscon, Arizona • Hot Springs, Arkansas + 46 more

Conditions: Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Residual Disease
Interventions: α-lactalbumin vaccine, Zymosan; Biological
Lead sponsor: George T. Budd; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Systemic Lupus Erythematosus
Interventions: Placebo, Belimumab 1 mg/kg, Belimumab 10 mg/kg; Drug
Lead sponsor: Human Genome Sciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 819 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 67
States / cities: Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 56 more

Conditions: Cutaneous Lupus Erythematosus
Interventions: Cutaneous Lupus educational script; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer
Interventions: Diffuse Optical Spectroscopy Imaging; Device
Lead sponsor: University of California, Irvine; Other
Eligibility: 21 Years to 75 Years · Female only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 2
States / cities: Irvine, California • Orange, California

Conditions: Triple Negative Breast Cancer
Interventions: Paclitaxel, Carboplatin, Nivolumab, Cabiralizumab, Tumor biopsy, Bone marrow, Blood draw; Drug · Biological · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Neoplasms, Metastases, Neoplasm
Interventions: Capecitabine, Exisulind; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Atopic Dermatitis
Interventions: CD2027 Ointment 3 mcg/g, twice daily, Vehicle Ointment, twice daily; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 14
States / cities: Hot Springs, Arkansas • San Diego, California • Denver, Colorado + 10 more

Conditions: Mucopolysaccharidosis Type I (MPS I), Mucopolysaccharidosis Type II (MPS II), Mucopolysaccharidosis Type III (MPS III), Mucopolysaccharidosis Type VI (MPS VI), Krabbe Disease
Interventions: Not listed
Lead sponsor: University of Chicago; Other
Eligibility: 1 Day to 18 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 3
States / cities: Chicago, Illinois • Minneapolis, Minnesota • Buffalo, New York

Conditions: Breast Cancer
Interventions: Exposure: Adjuvant chemotherapy treatment, Exposure: Adjuvant hormonal therapy treatment; Drug
Lead sponsor: Kessler Foundation; Other
Eligibility: 20 Years to 70 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: IBS (Irritable Bowel Syndrome), Bloating, Abdominal Pain, Gut Health
Interventions: FODMAP-targeting digestive enzyme blend, Placebo; Dietary Supplement · Other
Lead sponsor: Kiwi Health Inc; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Systemic Lupus Erythematosus (SLE)
Interventions: Health coach-led, online support program for people living with lupus; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Stem Cells
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab pegol; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 14
States / cities: Phoenix, Arizona • Covina, California • Upland, California + 10 more

Conditions: Prostate Cancer, Leukemia, Breast Cancer, Melanoma, Colorectal Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 64,277 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acne Rosacea
Interventions: ACCU-D1, Vehicle; Drug
Lead sponsor: Accuitis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Louisville, Kentucky • Austin, Texas

Conditions: Arthritis, Rheumatoid, Pain
Interventions: No intervention; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 5
States / cities: Denver, Colorado • Chicago, Illinois • Baltimore, Maryland + 2 more

Conditions: Acne Vulgaris
Interventions: CLS001 Topical Gel, CLS001 Topical Gel Vehicle; Drug
Lead sponsor: Maruho Co., Ltd.; Industry
Eligibility: 12 Years and older
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 20
States / cities: Encino, California • San Diego, California • Santa Monica, California + 17 more

Conditions: Lupus Nephritis
Interventions: Voclosporin High Dose, Voclosporin Low Dose, Placebo; Drug
Lead sponsor: Aurinia Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 14
States / cities: Los Angeles, California • Palo Alto, California • Gainesville, Florida + 11 more

Conditions: Rheumatoid Arthritis
Interventions: AZD9056, Etanercept, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 8
States / cities: Aventura, Florida • Orlando, Florida • Sarasota, Florida + 5 more

Conditions: Cancer, Skin Disease, Immunotherapy, Patients With Solid Tumors Receiving Immunotherapy With an ICI Will be Randomized to Participate in an SDoH and Side Effects Navigation Program vs. Control
Interventions: systemic corticosteroid or biologic; Drug
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years to 99 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Denver, Colorado • New York, New York

Conditions: Breast Carcinoma
Interventions: Exercise Intervention, Resting, Biomarker Analysis, Questionnaire Administration; Behavioral · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer

The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer

A Study of Belimumab in Subjects With Systemic Lupus Erythematosus

Effectiveness of a Knowledge-based Intervention for Patients With Cutaneous Lupus Erythematosus

Monitoring the Response of Chemotherapy on Breast Cancer Tumor by Photon Migration Spectroscopy

Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer

Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients

Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis

Lysosomal Storage Disease: Health, Development, and Functional Outcome Surveillance in Preschool Children

Chemotherapy Effect on Brain Structure, Neurophysiology and Psychomotor Behavior in Breast Cancer Patients

A Study Evaluating the Impact of Regular FODMAP-targeting Digestive Enzyme Blend Use on Gastrointestinal Symptoms in Individuals With Self-Reported Bloating

Whole Health Empowerment for Endotypes of Lupus: Improving Quality of Life in SLE

Isolation and Characterization of Mammary Stem Cells

Interpretations and Predictions of Patient Reported Outcomes by Breast Cancer Patients

A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis

Natural History Study of Early Life Exposures in Agriculture (ELEA)

Safety and Efficacy of ACU-D1 in the Treatment of Acne Rosacea

Chronic Pain in Rheumatoid Arthritis

Safety and Efficacy Study of CLS001Topical Gel Compared to Vehicle in Subjects With Inflammatory Acne Vulgaris

AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)

A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)

Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy

Acute Exercise Intervention in Breast Cancer Survivors